MTOR and neoplasm: The study conducted by Maruei-Milan et al. [44] on 131 PTC patients and 144 healthy controls found MTOR rs2295080 polymorphism to be associated with a decreased risk of PTC in dominant and allelic models and with a lower risk of a higher tumor stage in the dominant model.